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Abstracts
Background: Src family kinases (SFKs) play an important role in cancer proliferation, survival, motility, invasiveness,
metastasis, and angiogenesis. Among the SFKs, c-Src and c-Yes are particularly over-expressed or hyper-activated in
many human epithelial cancers. However, only a few studies have attempted to define the expression and role of
c-Src and c-Yes in cutaneous carcinomas.
Objectives: To investigate the expression of c-Src and c-Yes in cutaneous carcinomas to include malignant
melanoma (MM), squamous cell carcinoma (SCC) and basal cell carcinoma (BCC).
Methods: We examined 6 normal skin tissues and 18 malignant skin tumor tissues using western blotting for the
expression of c-Src and c-Yes. In another set, 16 specimens of MM, 16 SCCs and 16 BCCs were analyzed for the
expression of c-Src and c-Yes using immunohistochemical staining.
Results: Western blotting showed that c-Src was expressed in all malignant skin tumors, but not in normal skin,
while c-Yes was expressed in MM and SCC, but not in BCC and normal skin. Immunohistochemical staining results
of c-Src and c-Yes in MM, SCC, and BCC mirrored those of the western blot analysis.
Conclusions: c-Src, rather than c-Yes, plays a key role in the proliferation and progression of malignant skin
cancers.
Introduction
Skin tumors have become one of the most common
cancers in many countries, with rapid increasing inci-
dence during the last half century. Nonmelanoma skin
cancers including basal cell carcinoma (BCC) and squa-
mous cell carcinoma (SCC) now make up more than
one third of all cancers in the United States [1]. A large
number of studies regarding the role of oncogenes and
hormones, as well as environmental and predisposing
factors, have been reported.
Oncogenes, especially Src family kinases (SFKs), which
are activated in colon and breast cancers, are drawing
attention for their involvement in malignant melanoma
(MM) [2]. SFKs are non-receptor tyrosine kinases that
participate in variable cellular signal transduction path-
ways, with the capacity to trigger cancer with its
continuous activation. SFKs are composed of 9 mem-
bers, c-Src, c-Yes, Fyn, Lyn, Lck, Hck, Blk, Rgr, and Yrk.
SFKs play integral roles in cancer development to
include proliferation, survival, motility, invasiveness,
metastasis, and angiogenesis. Most SFKs are primarily
expressed from a hematopoietic cell origin, but c-Src, c-
Yes, and Fyn are expressed at high levels by platelets,
neurons, and some epithelial tissues [3]. c-Src and c-Yes
in particular are over-expressed or hyper-activated in
many human epithelial cancers. The role and process of
these two oncogenes in colon and breast cancer are well
studied, but not in other human cancers. The role of
SFKs in melanoma have been investigated with conflict-
ing reports, but their overall role in nonmelanoma skin
tumors has yet to be elucidated. Tyrosine kinases are
known to be activated in many human MM, SCC, and
BCC epithelial cancers. Therefore, we studied the
expression of c-Src and c-Yes to uncover its involve-
ment in malignant skin cancer development. * Correspondence: mkcho2001@hanmail.net
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Tissue samples
A total of 8 normal skin tissues and 24 malignant skin
tumor tissues were obtained from patients who under-
went surgery between July 2009 and September 2009 in
the Departments of Plastic and Reconstructive Surgery
at Hanyang University Guri Hospital and Soonchun-
hyang University Hospital in South Korea. Informed
consent was obtained from the patients before surgery.
The malignant skin tumor tissues, including 8 MM, 8
SCC, and 8 BCC, were obtained from patients who were
treated with excisional surgery. All tumor tissues were
examined using both conventional histopathological
confirmation and immunohistochemical studies to con-
firm the diagnosis. Clinical and histopathological data
are shown in Table 1. A portion of the specimens were
frozen in liquid nitrogen immediately after resection and
stored at -80°C degrees for subsequent western blot ana-
lysis. The human malignant melanoma cell line G361,
obtained from the American Type Culture Collection
(CRL 1424; Rockville, MD, USA), served as a positive
control for c-Src and c-Yes expression.
Western blot analysis
Tissue samples were homogenized in WCE buffer
[25 mM HEPES (pH 7.7), 0.3 M NaCl, 1.5 mM MgCl2,
0.2 mM ethylenediamine tetraacetic acid (EDTA), 0.1%
Triton X-100, 0.5 mM dithiothreitol (DTT), 20 mM-gly-
cerolphosphate, 0.1 mM Na3VO4, 2 g per mL leupeptin,
2 g per mL aprotinin, 1 mM phenylmethylsulfonyl fluor-
ide (PMSF), and a protease inhibitor cocktail tablet
(Boehringer Mannheim)]. The tissue suspension was
rotated at 4°C for 10 minutes. Supernatants were col-
lected and then kept at -70°C and used for western blot-
ting. Proteins from the tissue were separated by SDS-
PAGE using NuPAGE 4-12% bis-Tris gels (Invitrogen,
NP0335Box) and then transferred to Immobilon-P mem-
branes. The membrane was blocked using 5% BSA in
TBS-T (20 mM Tris, pH 7.6, 130 mM NaCl, and 0.1%
Tween 20) solution. 6 MM, 6 SCC, 6 BCC and 6 normal
skin tissues were then reacted with the primary antibody,
Src (36D10) rabbit mAb (Cell Signaling technology®,
#2109) and Yes antibody (Cell Signaling technology®,
#2734) diluted to 1:1,000 concentration, at 4°C for
16 hours. This was then followed by washing buffer and
TBST buffer washes (10 mM Tris-Cl, pH 8.0, 150 mM
NaCl, 0.05% Tween 20), 4 times for 10 minutes, 10 min-
utes, 15 minutes and 15 minutes and then reacted with
anti-rabbit IgG (Cell Signaling technology®, #7074)
-horseradish peroxidase-linked species-specific whole
antibody dilutes to 1:2,000 for 1 hour. After the reaction
with the secondary antibody, it was washed 4 times for
10 minutes, 10 minutes, 15 minutes and 15 minutes. Pro-
teins on the membrane were detected using an enhanced
chemiluminescence solution kit (Amersham, UK). The
membranes were stripped and reblotted with anti-actin
antibody (catalog number sigma A5441). Western blot-
ting analysis with mouse monoclonal antibody specific
for phospho-Src (Calbiochem-Novabiochem, San Diego,
CA) and mouse monoclonal antibody specific for phos-
pho-Yes (WAKO, Osaka, Japan), were carried out on the
2 MM, 2 SCC, 2 BCC and 2 normal skin as described.
Immunohistochemical staining
For immunohistochemical studies, the stored formalin-
fixed, paraffin-embedded samples that included, 16 MM,
16 SCC, and 16 BCC were used. Parraffin sections (4 μm)
were deparaffinized in xylene, rehydrated in 10 mM
citrate buffer (pH 6.0), and then heated in a microwave
oven for 15 minutes to restore antigens. To suppress
endogenous peroxidase within the tissues, the samples
were treated with 3% peroxide for 5 minutes, then with
blocking solution for 30 minutes. Slides were incubated
with primary Src (36D10) rabbit mAb and Yes antibody
in a humid chamber for 60 minutes. Tissue staining was
visualized with 3,3’-Diaminobenzidine (DAB) (ScyTek,
USA) substrate chromogen solution.
Table 1 Clinicopathological features of 24 malignant skin
tumors
Case No. Sex/Age Site Tumor type
1 M-1 F/53 Foot MM(ALM)
2 M-2 F/51 Lower back MM(NM)
3 M-3 M/70 Foot MM(NM)
4 M-4 M/66 Foot MM(NM)
5 M-5 M/54 Thigh MM(ALM)
6 M-6 M/65 Thumb MM(NM)
7 M-7 M/58 Foot MM(ALM)
8 M-8 M/63 Foot MM(SSM)
9 S-1 F/86 Temple SCC
10 S-2 F/76 Cheek SCC
11 S-3 M/51 Buttock SCC
12 S-4 F/86 Face SCC
13 S-5 F/87 Cheek SCC
14 S-6 F/74 Scalp SCC
15 S-7 F/82 Temple SCC
16 S-8 F/77 Cheek SCC
17 B-1 F/67 Cheek BCC
18 B-2 M/75 Nose BCC
19 B-3 M/52 Nose BCC
20 B-4 M/64 Nose BCC
21 B-5 F/68 Nose BCC
22 B-6 F/71 Lower lid BCC
23 B-7 F/65 Nose BCC
24 B-8 M/56 Cheek BCC
Abbreviations: MM, malignant melanoma; ALM, acral lentiginous melanoma;
NM, nodular melanoma; SSM, superficial spreading melanoma; SCC, squamous
cell carcinoma; BCC, basal cell carcinoma.
Levels of invasion of MM (M-1~M-7) were Clark’s Level IV, M-8 was Level I.
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The amount of expression in western blotting was mea-
sured with TINA software (Version 2.10e). Measured
amount of expression of malignant skin tumors was
compared to that of normal skin.
Statistical analysis
The data from the TINA score were analyzed using the




Western blot analysis was performed to determine the
expression of c-Src and c-Yes in 18 malignant skin
tumors and 6 normal skin tissues. c-Src was expressed
in all malignant skin tumors but not expressed in nor-
mal skin tissues, while c-Yes was expressed in MM and
SCC and not in BCC and normal skin (Fig. 1) (data not
shown for M-5, M-6, S-5, S-6, B-5, B-6, N-5, N-6). The
expression amount score in western blotting was mea-
sured by TINA software (Version 2.10e), and the aver-
age TINA score of c-Src was 0.006 in normal skin,
1.143 in MM, 1.027 in SCC, and 0.590 in BCC. The
average TINA score of c-Yes was 0.011 in normal skin,
0.374 in MM, 1.054 in SCC, and 0.012 in BCC. There
were significant differences in the TINA scores of c-Src
between malignant skin tumors and normal skin (p =
0.002). Of the tumor tissues, significant differences in c-
Src score among the tumors (p = 0.002) were noted.
With regard to c-Yes expression, there were significant
differences in the TINA scores between two skin tumors
(MM and SCC) and normal skin (p = 0.002), and there
was no significant difference between BCC and normal
skin (p = 0.818). The expression amount score based on
w e s t e r nb l o t t i n gi sg r a p h e di nF i g .2 .T oc o n f i r mt h e
expression in phosphate form, western blot analysis with
phospho-Src and phospho-Yes was also performed in 2
MM, 2 SCC, 2 BCC and 2 normal skin tissues. Phos-
pho-Src was expressed in all malignant skin tumors and
not expressed in normal skin tissues and phospho-Yes
w a se x p r e s s e di nM Ma n dS C Cb u tn o ti nB C Ca n d
normal skin (Fig. 3).
Immunohistochemical examination
Immunohistochemical study showed that the staining
pattern of c-Src and c-Yes in MM, SCC and BCC corre-
lated with western blot analysis. c-Src protein was
expressed in MM and SCC with moderate positivity,
and BCC with mild positivity (Fig. 4). c-Yes was
expressed in MM with moderate positivity and SCC
with strong positivity, but not in BCC (Fig. 5).
Discussion
The activation and functions of SFKs have been more
investigated and better characterized in colon cancer
and breast cancer compared to skin cancers. In colon
cancer studies, c-Src protein level and kinase activity in
the early-stages of colon cancer were found to be
greater than in normal colonic mucosa [4,5]. The activ-
ity was highest in moderately to well-differentiated colo-
nic lesions, while poorly differentiated carcinomas and
Figure 1 Western blot analysis for c-Src and c- Yes in malignant skin tumor and normal skin. (A) c-Src was expressed in malignant
melanomas (MM) (M-1 - M-4), squamous cell carcinomas (SCC) (S-1 - S-4) and basal cell carcinomas (BCC) (B-1 - B-4), but not in normal skin
(N-1 - N-4). (B) c-Yes was expressed in MM, SCC, but not in BCC and normal skin.
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ity [6]. Therefore, c-Src activity is directly related to the
malignant potential of the cells, providing evidence that
its activation contributes to the progression of colon
cancer in the early and developing stages. SFKs also play
an important role in the progression of breast cancers.
SFK expression, as measured by immunoblotting with
an antibody specifically recognizing Src, Fyn, and Yes,
were elevated in 25 of 52 breast tumors. c-Src kinase
and STAT3 activated hepatocyte growth factor expres-
sion in breast carcinoma cells [7,8]. Enhanced c-Src
activity is also one potential mechanism leading to
tamoxifen-resistant growth in breast cancer, and activa-
tion of c-Src and Fak has a close relationship with
Figure 2 The score of expression amount using western blotting. (A) c-Src, (B) c-Yes.
Figure 3 Western blot analysis for phospho-Src and phospho-Yes in malignant melanoma (M-7, M-8), squamous cell carcinoma (S-7,
S-8), basal cell carcinoma (B-7, B-8) and normal skin (N-7, N-8). The expression pattern of the phosphate form mirrored that of the total
form.
Lee et al. Journal of Experimental & Clinical Cancer Research 2010, 29:116
http://www.jeccr.com/content/29/1/116
Page 4 of 7Figure 4 Immunohistochemical staining of c-Src in (A) malignant melanoma (MM), (B) squamous cell carcinoma (SCC) and (C) basal
cell carcinoma (BCC). c-Src protein is expressed in MM and SCC with moderate positivity, and BCC with mild positivity.
Figure 5 Immunohistochemical staining of c-Yes in (A) malignant melanoma (MM), (B) squamous cell carcinoma (SCC) and (C) basal
cell carcinoma (BCC). c-Yes was expressed in MM with moderate positivity and SCC with strong positivity, but was negative in BCC.
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breast cancer [9]. In recent studies, elevated c-Src activ-
ity was directly involved in the disruption of cell-cell
adhesions in tamoxifen-resistant breast cancer cell lines,
indicating that activated c-Src plays a role in the mislo-
calization of adhesion proteins [10]. Therefore, c-Src
and c-Yes play important roles in colon cancer and
breast cancer.
However, a very small number of studies have been
conducted on SFK expression in skin cancer, and there
is some controversy as to whether c-Src or c-Yes affects
melanoma. By measuring tyrosine-specific kinase activity
for c-Src expression in human melanoma tissues kinase
activity in melanoma was found to be greater than that
in normal skin regardless of the type of melanoma or
the metastatic site [11]. In one study, Src kinase inhibi-
tor dasatinib inhibited melanoma cell migration and
invasion by inducing cell cycle arrest and apoptosis [12].
STAT3, which has been shown to play an important
role in tumor cell proliferation and survival, and c-Src
tyrosine kinase are activated in melanoma cell lines.
Melanoma cells undergo apoptosis when either Src
kinase activity or STAT3 signaling is inhibited [13]. This
supports the fact that Src activated STAT3 signaling has
a key role in the survival and growth of melanoma
tumor cells. c-Src activation also affects epidermal
growth factor of STAT in head and neck SCCs and pro-
motes the invasion and progression of SCC [14-16].
On the contrary, it has been reported that c-Yes
expression and kinase activity in human melanoma cell
lines are greater than that in normal melanocyte cell
lines, and that c-Src expression and activity are not dif-
ferent in human melanoma cell lines compared to nor-
mal melanocyte cell lines [17]. Similarly, it was
demonstrated in another study that c-Yes tyrosine
kinase was activated more in human brain-metastatic
melanoma cell lines by stimulation of neurotropin and
nerve growth factor, whereas c-Src was not affected
[18]. These results show that c-Yes is more important
than c-Src in melanoma progression and metastasis.
Therefore, we studied the expression of both c-Src and
c-Yes in overall human skin cancer tissues including
M M ,S C C ,a n dB C Cu s i n gw e s t ern blotting and immu-
nochemistry. Our study results show that c-Src was
expressed in all skin cancer tissues, but not in normal
skin tissues. c-Yes was expressed in MM and SCC, but
not in normal skin tissues or BCC. c-Src was found to
be significantly more expressed in MM, followed by
SCC and BCC by both western blotting and immunohis-
tochemistry, and c-Yes was intensely expressed in SCC.
In general, MM is the most invasive of the skin tumors,
followed by SCC and BCC. Given these facts, our results
suggest that c-Src is expressed more in highly aggressive
skin tumors, while c-Yes is expressed more in SCC
compared to other skin cancers. We also confirmed that
the expression pattern for phosphate Src and Yes forms
in skin cancers were similar to the total forms. There-
fore, we believe that c-Src, rather than c-Yes, plays a
key role in the proliferation and progression of malig-
nant skin cancers.
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